Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Zepp Health Corp. Reports Fourth Quarter and Full Year 2020 Unaudited Financial Results


      News provided by

      Zepp Health Corp.

      Mar 15, 2021, 06:05 ET

      Share this article

      Share this article


      BEIJING, March 15, 2021 /PRNewswire/ -- Zepp Health Corp. (NYSE: ZEPP) today reported revenue of RMB2.0 billion, or US$302.3 million; GAAP diluted net income per share of RMB0.44 (US$0.07), or GAAP diluted net income per ADS of RMB1.76 (US$0.27) for the fourth quarter ended December 31, 2020.

      The small year-over-year decrease in fourth quarter revenue was mainly the result of a 20.8% decrease in revenue from Xiaomi products, partially offset by 25.1% growth and geographic expansion of Amazfit and Zepp-branded products. Unit shipments were affected by the timing of the new product introduction, seasonality and continued impact of Covid, with some reduced production availability and lockdowns in many of our key European markets," said Wang Huang, Chairman and CEO of Zepp Health. "I am proud that despite these challenges, our self-branded products performed strongly across many price points. In the fourth quarter, we also made important progress in our data analytics business, and industrial health tech, as demonstrated by a number of announcements, leading us to changing the company's name recently to better reflect our broad mission of connecting health with technology. We are well positioned to have a strong 2021."

      Fourth Quarter and Full Year 2020
      Financial Summary









      For the Three Months Ended


      For the Full Year Ended

      GAAP in millions, except percentages and per share
      amounts


      Dec. 31, 2020

      Dec. 31, 2019[1]


      Dec. 31, 2020

      Dec. 31, 2019[1]

      Revenue RMB


      1,972.5

      2,111.4


      6,433.4

      5,812.3

      Revenue USD


      302.3

      303.3


      986.0

      834.9

      Gross Margin


      19.0%

      23.8%


      20.7%

      25.3%

      Net income attributable to Zepp Health Corp.
      RMB


      115.2

      207.2


      228.8

      575.2

      Adjusted net income attributable to Zepp
      Health Corp. RMB[2]


      128.4

      213.8


      293.9

      630.3








      Diluted net income per share RMB


      0.44

      0.80


      0.88

      2.24

      Diluted net income per ADS USD


      0.27

      0.46


      0.54

      1.29

      Adjusted diluted net income per share RMB[3]


      0.49

      0.83


      1.13

      2.45

      Adjusted diluted net income per ADS USD


      0.30

      0.48


      0.69

      1.41

      Units Shipped


      13.3

      14.7


      45.7

      42.3

      [1] The USD numbers in 2019 are referenced with the prior 6-K disclosures.

      [2] Adjusted net income attributable to Zepp Health Corp. is a non-GAAP measure, which excludes share-based compensation expenses. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

      [3] Adjusted diluted net income is the abbreviation of Adjusted net income attributable to ordinary shareholders of Zepp Health Corp., which is a non-GAAP measure and excludes share-based compensation expenses attributable to ordinary shareholders of Zepp Health Corp., and is used as the numerator in computation of adjusted basic and diluted net income per ADS attributable to ordinary shareholders of Zepp Health Corp.

      Added Chief Financial Officer, Leon Deng, "Fourth quarter revenue was in-line with our guidance range, largely due to the return to Covid lockdowns in many areas of Europe over the year-end holidays, as well as some continuing inventory availability issues for new products. Product mix and volume impacted gross margin, but good expense discipline continued in the quarter, both in absolute amounts as well as operating expenses as a percentage of sales. Looking ahead, investments in personnel-related costs to accelerate growth of Amazfit and Zepp-branded products worldwide are creating a slightly higher fixed-cost base in our operating model, which we will try to offset as much as possible by further variable cost savings. Guidance for the first quarter 2021 reflects the seasonality of business, but our outlook for 2021 remains strong."

      Management's Discussion and Analysis

      Fourth Quarter 2020

      Revenue

      Total units shipped in the fourth quarter 2020 decreased 9.5% year-over-year to 13.3 million, compared with 14.7 million in the fourth quarter of 2019. This was driven by a 14.5% decrease in units of products built for Xiaomi, partially offset by a 31.3% increase in product units under the company's own brands.

      Fourth quarter revenues reached RMB1,972.5 million (US$302.3 million), a decrease of 6.6% from the fourth quarter of 2019. Revenue from Xiaomi products decreased 20.8% and revenue from self-branded products increased 25.1%, primarily driven by our new products including Amazfit Pop, Bip, Neo, and the GT series. Quarterly sales of self-branded products grew mid-teens to mid-thirties percentages year-over-year each quarter of 2020, and the company expects that trend to continue. Both sequential and year-over-year quarterly revenue changes can be affected by the seasonality of purchase patterns as well as by timing of new product introductions.

      Covid-19 Impact

      As was true in the third quarter, in the fourth quarter 2020, the company experienced production delays that affected inventory availability for some new products. Also, many European countries re-instituted lockdowns, which we believe tempered holiday sales in some of the company's strongest markets. North American markets, which were less restricted, were stronger, but were affected somewhat by product availability.

      Gross Margin

      Gross margin in the fourth quarter 2020 was 19.0%, compared with 23.8% in the year-ago period. Margin on both Xiaomi and self-branded products in the fourth quarter was lower than the year-ago fourth quarter. For self-branded products, discounting on older models and holiday promotional discounts had a greater impact than in the year-ago quarter. Gross margin and gross profit are affected by product mix as different products have different margin contributions, and these can change over the life of a product. 

      Research & Development

      Fourth quarter 2020 R&D expense was RMB129.6 million, decreasing 7.5% year-over year, and comprising 6.6% of revenue. This reflects effective expense control in R&D activities, specifically in better resource consumption management during testing process. The company optimized its integrated product development process to effectively develop new smart devices and analytics for consumers and industry.

      Sales & Marketing

      Sales and Marketing expense for the fourth quarter 2020 was RMB116.9 million, increasing 86.2% year-over-year, and comprising 5.9% of revenue, compared to 3.0% of revenue in the year-ago period. Higher sales and marketing expense in 2020 was driven by increased headcount for sales, marketing and support as sales of self-branded products have expanded globally. In the fourth quarter 2020, there were 27 countries in which the company had 100,000 or more device activations, compared to 9 in the fourth quarter of 2019. Product launch activities for a higher number of new products in 2020's fourth quarter, as well as a higher number of regions in which product launch and promotional activities were conducted, contributed to the increase in expense. 

      General & Administrative

      General and Administrative expense was RMB64.5 million, decreasing 21.9% year-over-year, and comprising 3.3% of revenue, compared to 3.9% in the year-ago period.

      Operating Income and Expenses

      Total Operating Expense for the fourth quarter 2020 was RMB310.9 million, up 8.9% from the year-ago period, comprising 15.8% of revenue in the fourth quarter 2020, compared to 13.5% in the fourth quarter 2019. After rising significantly in the second quarter of 2020 to 21.5% of sales, expense reductions reduced it to 17.0% in the third quarter and 15.8% in the fourth quarter. In value, total operating expense declined sequentially from the third quarter 2020 to the fourth quarter 2020 by RMB68.6 million, or 18.1% due to effective expense management. The company will continue to exercise control on expenses in the future, improving the operating efficiency as a whole.

      Operating Income for the fourth quarter 2020 was RMB63.7 million, down 70.7% from RMB217.7 million from the year-ago period.

      Liquidity and Capital Resources

      At December 31, 2020, the Company had cash and cash equivalents of RMB2,273.3 million (US$348.4 million), compared with RMB1,803.1 million as of December 31, 2019.

      Full Year 2020

      Revenue

      Total units shipped in the full year 2020 increased 8.0% from full year 2019, reaching 45.7 million, compared with 42.3 million in the full year of 2019. The total shipments of Zepp Health comprised fitness bands, smart watches, smart scales, ear buds and other smart fitness devices.

      Full year 2020 revenues reached RMB6,433.4 million (US$986.0 million), an increase of 10.7% from the full year of 2019. The increase in the year was driven primarily by both sales of the Xiaomi wearable products and Amazfit and Zepp-branded products.

      Reflecting global market expansion and a broadening product line, For the full year 2020, Zepp Health self-branded products increased 20.5% in unit shipments to comprise 10.3% of total unit sales and 31.0% of total revenue, compared to 27.8% of revenue in 2019.

      Gross Margin

      Gross margin in the full year 2020 was 20.7%, compared with 25.3% in the full year 2019. The decrease was mainly driven by the lower margin of Xiaomi products and lower margins on newly introduced self-branded products.

      Research & Development

      Full year 2020 R&D expense was RMB538.0 million, increasing 24.9% from the full year 2019, and comprised 8.4% of revenue, compared to 7.4% of revenue in the full year 2019, reflecting personnel additions and expansion of R&D activities for future products and new product categories. This was partially offset by lower resource consumption in testing procedures. The company optimized its integrated product development process to effectively develop new smart products and services to the consumers, and believed that smart R&D investment was a key factor to maintain its competitive position in the global market.

      Sales & Marketing

      Sales and Marketing expense for the full year 2020 was RMB358.7 million, increasing 97.1% from the full year 2019, and comprised 5.6% of revenue, compared to 3.1% of revenue in the full year 2019. The increase was driven by investments in global expansion of Amazfit and Zepp-branded products, requiring staffing and promotional expenses. The company also launched 20 plus different new self-branded products or product versions, about 4-5 times the size of last year, requiring greater promotional expenses.

      General & Administrative

      General and Administrative expense was RMB261.8 million for the full year 2020, increasing 5.4% from the full year 2019, and comprised 4.1% of revenue, compared to 4.3% in the full year 2019. The increase is primarily due to increase in office expansion and professional fees.

      Operating Income and Expense

      Operating Expense for the full-year 2020 increased 34.5% over 2019. Operating expense for the four quarters of 2020 represented, chronologically, 20.6%, 21.5%, 17.0% and 15.8% of revenue, as expense management was undertaken in the third quarter. 

      Outlook

      For the first quarter of 2021, the management of the Company currently expects:

      - Net revenues to be between RMB1.0 billion and RMB1.15 billion, compared with RMB1.09 billion in the first quarter of 2020.

      The above outlook is based on the current market conditions and reflects the Company management's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

      Conference Call

      The Company's management will hold a conference call at 8:00 a.m. Eastern Time on Monday, March 15, 2021 (8:00 p.m. Beijing Time on March 15, 2021) to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:

      US (Toll Free):

      +1-888-346-8982

      International:

      +1-412-902-4272

      Mainland China (Toll Free):

      400-120-1203

      Hong Kong (Toll Free):

      800-905-945

      Hong Kong:

      +852-3018-4992

      Participants should dial-in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corp."

      Additionally, a live and archived webcast of the conference call will be available at https://ir.zepp.com/investor.

      A telephone replay will be available one hour after the call until March 22, 2021 by dialing:

      US Toll Free:

      +1-877-344-7529

      International:

      +1-412-317-0088

      Replay Passcode:

      20210315

      About Zepp Health Corporation (NYSE: ZEPP)

      Zepp Health changed its name from Huami Corp. (HMI) on February 25, 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. The company's mission continues to be connecting health with technology. Since its inception in 2013, Zepp Health has developed a platform of proprietary technology including AI chips, biometric sensors, and data algorithms, which drive a broadening line of smart health devices for consumers, data analytics services for population health, and industrial medical technology for diagnostics and care delivery. Zepp Health is one of the largest global developers of smart wearable health and consumer fitness devices, shipping 46 million units in 2020. Zepp Health Corp. is based in Hefei, China, with U.S. operations, Zepp Health USA, based in Cupertino, Calif.

      Use of Non-GAAP Measures

      We use adjusted net income, a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted net income represents net income excluding share-based compensation expenses, and such adjustment has no impact on income tax. Adjusted net income attributable to ordinary shareholders of Zepp Health Corp. is a non-GAAP measure, which excludes share-based compensation expenses attributable to ordinary shareholders of Zepp Health Corp., and is used as the numerator in computation of adjusted net income per share attributable to ordinary shareholders of Zepp Health Corp.

      We believe that adjusted net income and adjusted net income attributable to ordinary shareholders help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income and net income attributable to ordinary shareholders. We believe that adjusted net income and adjusted net income attributable to ordinary shareholders provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

      Adjusted net income and adjusted net income attributable to ordinary shareholders, should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per share attributable to ordinary shareholders of Zepp Health Corp. or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted net income and adjusted net income attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

      Exchange Rate

      The Company's business is primarily conducted in China and the significant majority of revenues generated are denominated in Renminbi ("RMB"). This announcement contains currency conversions of RMB amounts into U.S. dollars ("US$") solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ are made at a rate of RMB6.5250 to US$1.00, the effective noon buying rate for December 31, 2020 as set forth in the H.10 statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on December 31, 2020, or at any other rate.

      Safe Harbor Statement

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the cooperation with Xiaomi, the recognition of the Company's self-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions in China and the global. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

      For investor and media inquiries, please contact:

      In China:
      Zepp Health Corp.
      Grace Yujia Zhang
      E-mail: [email protected]

      The Piacente Group, Inc.
      Yang Song
      Tel: +86-10-6508-0677
      E-mail: [email protected]

      In the United States:
      Zepp Health Corp.
      Brad Samson
      Tel: 1+714-955-3951
      E-mail: [email protected] 

      Zepp Health Corp.

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)









      As of December 31,


      As of December 31,



      2019


      2020



      RMB


      RMB


      US$








      Assets







      Current assets:







      Cash and cash equivalents


      1,803,117


      2,273,349


      348,406

      Restricted cash


      874


      2,401


      368

      Term deposit


      -


      5,000


      766

      Accounts receivable


      188,940


      298,038


      45,676

      Amounts due from related parties, current


      1,421,170


      860,213


      131,833

      Inventories


      893,806


      1,217,537


      186,596

      Short-term investments


      17,187


      18,430


      2,825

      Prepaid expenses and other current assets


      67,358


      152,898


      23,433

      Total current assets


      4,392,452


      4,827,866


      739,903








      Property, plant and equipment, net


      64,350


      124,619


      19,099

      Intangible asset, net


      85,753


      145,213


      22,255

      Goodwill


      5,930


      62,515


      9,581

      Long-term investments


      406,099


      443,986


      68,044

      Deferred tax assets


      102,649


      120,190


      18,420

      Other non-current assets


      8,828


      28,165


      4,316

      Non-current operating lease right-of-use assets


      108,682


      151,165


      23,167

      Total assets


      5,174,743


      5,903,719


      904,785

      Zepp Health Corp.

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)









      As of December 31, 


      As of December 31,



      2019


      2020



      RMB


      RMB


      US$








      Liabilities







      Current liabilities:







      Accounts payable


      1,999,951


      1,951,335


      299,055

      Advance from customers


      44,793


      42,502


      6,514

      Amount due to related parties, current


      14,769


      11,185


      1,714

      Accrued expenses and other current liabilities


      352,249


      252,275


      38,663

      Income tax payables


      67,854


      27,706


      4,246

      Notes payable


      2,184


      -


      -

      Bank borrowings


      -


      504,671


      77,344

      Total current liabilities


      2,481,800


      2,789,674


      427,536

      Deferred tax liabilities


      5,399


      22,374


      3,429

      Long-term borrowing


      -


      60,000


      9,195

      Other non-current liabilities


      113,596


      185,168


      28,378

      Non-current operating lease liabilities


      76,360


      116,245


      17,815

      Total liabilities


      2,677,155


      3,173,461


      486,353

      Zepp Health Corp.


      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")


      except for number of shares and per share data, or otherwise noted)











      As of December 31,


      As of December 31,



      2019


      2020



      RMB


      RMB


      US$








      Equity







      Ordinary shares


      155


      157


      24

      Additional paid-in capital


      1,478,902


      1,552,109


      237,871

      Accumulated retained earnings


      910,612


      1,133,368


      173,696

      Accumulated other comprehensive income


      111,081


      44,624


      6,841

      Total Zepp Health Corp. shareholders' equity


      2,500,750


      2,730,258


      418,432

      Non-controlling interests


      (3,162)


      -


      -

      Total equity


      2,497,588


      2,730,258


      418,432

      Total liabilities and equity


      5,174,743


      5,903,719


      904,785

      Zepp Health Corp.

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)



      For the Three Months Ended December 31,


      2019


      2020


      RMB


      RMB


      US$







      Revenues

      2,111,413


      1,972,535


      302,304

      Cost of revenues

      1,608,288


      1,597,889


      244,887

      Gross profit

      503,125


      374,646


      57,417

      Operating expenses:






      Selling and marketing

      62,756


      116,853


      17,909

      General and administrative

      82,562


      64,512


      9,887

      Research and development

      140,153


      129,575


      19,858

      Total operating expenses

      285,471


      310,940


      47,654

      Operating income

      217,654


      63,706


      9,763

      Other income and expenses:






      Realized gain from investment 

      1,822


      -


      -

      Gain from deconsolidation of a subsidiary

      -


      56,522


      8,663

      Interest income

      10,274


      14,450


      2,215

      Other income (expenses), net

      7,744


      (9,780)


      (1,499)

      Gain from fair value change of long-term investment

      -


      7,728


      1,184

      Income before income tax

      237,494


      132,626


      20,326

      Income tax expenses

      (27,335)


      (18,198)


      (2,789)

      Income before loss from equity method investments

      210,159


      114,428


      17,537

      Net income (loss) from equity method investments

      (3,759)


      722


      111

      Net income

      206,400


      115,150


      17,648

      Less: Net loss attributable to non-controlling interest

      (811)


      (54)


      (8)

      Net income attributable to Zepp Health Corp.

      207,211


      115,204


      17,656

      Net income attributable to ordinary shareholders of Zepp Health
      Corp.

      207,211


      115,204


      17,656

      Net income per share attributable to ordinary 






      shareholders of Zepp Health Corp.






      Basic income per ordinary share

      0.84


      0.46


      0.07

      Diluted income per ordinary share

      0.80


      0.44


      0.07







      Net income per ADS (4 ordinary shares equal to 1 ADS)



      ADS – basic

      3.36


      1.85


      0.28

      ADS – diluted

      3.21


      1.76


      0.27







      Weighted average number of shares used in computing net
      income per share






      Ordinary share – basic

      246,929,507


      249,632,609


      249,632,609

      Ordinary share – diluted

      258,484,867


      261,623,610


      261,623,610

      Zepp Health Corp.

      Reconciliation of GAAP and Non-GAAP Results

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      For the Three Months Ended December 31,



      2019


      2020



      RMB


      RMB


      US$

      Net income attributable to Zepp Health Corp.


      207,211


      115,204


      17,656

      Share-based compensation expenses


      6,549


      13,218


      2,026

      Adjusted net income attributable to Zepp Health Corp.


      213,760


      128,422


      19,682

















      For the Three Months Ended December 31,



      2019


      2020



      RMB


      RMB


      US$








      Net income attributable to ordinary shareholders
      of Zepp Health Corp.


      207,211


      115,204


      17,656

      Share-based compensation expenses attributable to
      ordinary shareholders of Zepp Health Corp.


      6,549


      13,218


      2,026

      Adjusted net income attributable to ordinary 
      shareholders of Zepp Health Corp.[2]


      213,760


      128,422


      19,682








      Adjusted net income per share attributable to 
      ordinary shareholders of Zepp Health Corp.







      Adjusted basic income per ordinary share


      0.87


      0.51


      0.08

      Adjusted diluted income per ordinary share


      0.83


      0.49


      0.08








      Adjusted net income per ADS (4 ordinary shares equal
      to 1 ADS)







      ADS – basic


      3.46


      2.06


      0.32

      ADS – diluted


      3.31


      1.96


      0.30








      Weighted average number of shares used in 
      computing net income per share







      Ordinary share – basic


      246,929,507


      249,632,609


      249,632,609

      Ordinary share – diluted


      258,484,867


      261,623,610


      261,623,610








      Share-based compensation expenses included 
      are follows:







      Cost of revenues


      8


      -


      -

      Selling and marketing


      641


      805


      123

      General and administrative


      4,145


      9,642


      1,478

      Research and development


      1,755


      2,771


      425

      Total


      6,549


      13,218


      2,026

      Zepp Health Corp.


      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")


      except for number of shares and per share data, or otherwise noted)






      Years Ended December 31,



      2019


      2020



      RMB


      RMB


      US$








      Revenues


      5,812,255


      6,433,363


      985,956

      Cost of revenues


      4,344,512


      5,100,698


      781,716

      Gross profit


      1,467,743


      1,332,665


      204,240

      Operating expenses:







      Selling and marketing


      181,975


      358,655


      54,966

      General and administrative


      248,462


      261,805


      40,123

      Research and development


      430,822


      538,009


      82,453

      Total operating expenses


      861,259


      1,158,469


      177,542

      Operating income


      606,484


      174,196


      26,698

      Other income and expenses:







      Realized gain from investment


      1,822


      -


      -

      Gain from deconsolidation of a subsidiary


      -


      56,522


      8,663

      Interest income


      33,478


      46,118


      7,068

      Other income (expenses), net


      10,586


      (23,552)


      (3,610)

      Gain from fair value change of long-term investment


      -


      12,325


      1,888

      Income before income tax


      652,370


      265,609


      40,707

      Income tax expenses


      (77,887)


      (31,154)



      (4,775)

      Income before loss from equity method investments


      574,483


      234,455


      35,932

      Net loss from equity method investments


      (1,112)


      (4,749)



      (728)

      Net income


      573,371


      229,706


      35,204

      Less: Net income (loss) attributable to non-controlling interest


      (1,825)


      953



      146

      Net income attributable to Zepp Health Corp.


      575,196


      228,753


      35,058

      Less: Undistributed earnings allocated to participating nonvested restricted shares


      2,450


      -


      -

      Net income attributable to ordinary shareholders of Zepp Health Corp.


      572,746


      228,753


      35,058

      Net income per share attributable to ordinary 
      shareholders of Zepp Health Corp.







      Basic income per ordinary share


      2.35


      0.92


      0.14

      Diluted income per ordinary share


      2.24


      0.88


      0.13








      Net income per ADS (4 ordinary shares equal to 1 ADS)







      ADS – basic


      9.40


      3.68


      0.56

      ADS – diluted


      8.95


      3.51


      0.54








      Weighted average number of shares used in computing net income per share

      Ordinary share – basic


      243,648,186


      248,470,684


      248,470,684

      Ordinary share – diluted


      255,959,172


      260,351,994


      260,351,994

      Zepp Health Corp.

      Reconciliation of GAAP and Non-GAAP Results

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      Years Ended December 31,



      2019


      2020



      RMB


      RMB


      US$

      Net income attributable to Zepp Health Corp.


      575,196


      228,753


      35,058

      Share-based compensation expenses


      55,128


      65,154


      9,985

      Adjusted net income attributable to Zepp Health Corp.


      630,324


      293,907


      45,043

















      Years Ended December 31,



      2019


      2020



      RMB


      RMB


      US$








      Net income attributable to ordinary shareholders of Zepp Health Corp.


      572,746


      228,753


      35,058

      Share-based compensation expenses attributable

      to ordinary shareholders of Zepp Health Corp.


      54,893


      65,154


      9,985

      Adjusted net income attributable to ordinary 
      shareholders of Zepp Health Corp.[2]


      627,639


      293,907


      45,043








      Adjusted net income per share attributable to 
      ordinary shareholders of Zepp Health Corp.







      Adjusted basic income per ordinary share


      2.58


      1.18


      0.18

      Adjusted diluted income per ordinary share


      2.45


      1.13


      0.17








      Adjusted net income per ADS (4 ordinary shares equal to 1 ADS)







      ADS – basic


      10.30


      4.73


      0.73

      ADS – diluted


      9.81


      4.52


      0.69








      Weighted average number of shares used in 
      computing net income per share







      Ordinary share – basic


      243,648,186


      248,470,684


      248,470,684

      Ordinary share – diluted


      255,959,172


      260,351,994


      260,351,994








      Share-based compensation expenses included 
      are follows:







      Cost of revenues


      55


      (54)


      (8)

      Selling and marketing


      3,198


      2,625


      402

      General and administrative


      40,684


      38,605


      5,916

      Research and development


      11,191


      23,978


      3,675

      Total


      55,128


      65,154


      9,985

      SOURCE Zepp Health Corp.

      Modal title

      Also from this source

      Zepp Health Corporation to Report Third Quarter 2026 Financial Results on November 22, 2026

      Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that ...

      Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results

      Zepp Health Corporation (NYSE: ZEPP) ("Zepp", the "Company" or "we") today announced its unaudited financial results for the second quarter of 2026....

      More Releases From This Source

      Explore

      Banking & Financial Services

      Banking & Financial Services

      Consumer Electronics

      Consumer Electronics

      Computer & Electronics

      Computer & Electronics

      Sports Equipment & Accessories

      Sports Equipment & Accessories

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.